Multiple insiders have executed 6 significant purchases totaling over $421,000 in the past month, demonstrating remarkable confidence in
$TriSalus Life Sciences (TLSI.US)$. This insider accumulation comes alongside impressive Q4 results showing 44% YoY revenue growth to $8.3M and full-year 2024 revenue up 59% to $29.4M. 🚀Worth watching this emerging player in the $4.56B cancer therapeutics market! Read our complete analysis: TriSalus Life Sciences Because Its Approach to Cancer Therapy Stands Out | Investment Review
...
